US equities |
NVDA $239.63 ▲+2.43% SPCX $169.87 ▲+6.86% MU $1,061.89 ▼-1.21% TSLA $379.94 ▲+2.52% SNDK $1,701.91 ▼-1.05% MSFT $528.11 ▲+2.04% INTC $116.15 ▼-2.66% META $742.76 ▲+2.02%
FinancialContent

Articles published by Bio-Path Holdings, Inc.

News headline image
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Provides Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Reports Full Year 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Expands Global Patent Portfolio
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Provides Key Clinical Updates
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Provides 2025 Clinical and Operational Update
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces Publication in Biomedicines
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Provides Clinical Update and Expansion Plans
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings Reports First Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH
News headline image
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Tickers BPTH